| Cat.No. | Name | Information |
|---|---|---|
| M40697 | NX-5948 | NX-5948 (BTK-IN-24) is an orally active, blood-brain barrier-penetrating, BTK-targeting degradation agent for the study of B-cell malignancies and autoimmune diseases. NX-5948 induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. NX-5948 mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. |
| M10423 | DT2216 | DT2216 is a BCL-XL protein hydrolysis targeting chimera (PROTAC) that ligates and degrades BCL-XL with E3 ubiquitin (E3) ligase. DT2216 is effective against a variety of BCL-XL-dependent leukemias and cancer cells. |
| M49369 | KP-14 | KP-14, a KRAS-PROTAC inhibitor with a similar structure to LC-2, inhibits the MAPK signaling pathway in NCI-H358 cells by binding to KRAS G12C via an acrylamide warhead and recruiting the E3 ligase CRBN, leading to rapid and sustained degradation of KRAS G12C. In addition, KP-14 exhibited potent antiproliferative activity against NCI-H358 cancer cells and was able to inhibit the formation of NCI-H358 tumor colonies, with an IC50 value of 17.41 μmol/L against the proliferation of NCI-H358 cells . |
| M45400 | ACBI2 | ACBI2 is a potent, orally active VHL PROTAC SMARCA2 degrader (EC50: 7 nM) that degrades SMARCA2 (DC50: 1 nM in RKO cells).ACBI2 can be used in lung cancer research. |
| M45356 | HJM-561 | HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC.HJM-561 preserves the activity of cells expressing wild EGFR, and a mouse model shows inhibition of 19del//T790M/C797S, overcoming Osimertinib resistance. Possesses anti-tumor activity. |
| M45166 | LWY713 | LWY713 is a PROTAC molecule targeting FLT3 with acetyl group as linker, which can selectively induce FLT3 degradation in CRBN and proteasome-dependent manner, with a DC50 of 0.64 nM and a Dmax of 94.8%, and possesses antitumor activity. |
| M45098 | CPS2 | CPS2 is a first-in-class, highly potent, selective, and irreversible PROTAC CDK2 degrader (IC50= 24 nM) for AML-related studies. |
| M43466 | YD23 | YD23 is a SMARCA2 PROTAC. YD23 induces degradation of SMARCA2. |
| M43465 | CST626 | CST626 is a pan-IAP degrader PROTAC. |
| M43464 | BacPROTAC-1 | BacPROTAC-1 is a mSA BacPROTAC degrader. |
| M43463 | ML 2-23 | ML 2-23 is a potent PROTAC BCR-ABL degrader. |
| M43462 | PROTAC SOS1 degrader-4 | PROTAC SOS1 degrader-4 is a potent SOS1 degrader. |
| M43461 | MS15 TFA | MS15 TFA is a potent and selective AKT PROTAC degrader. |
| M43460 | PROTAC BCR-ABL Degrader-1 | PROTAC BCR-ABL Degrader-1 is a PROTAC with a 2-oxoethyl linker. |
| M43459 | PROTAC CDK9 degrader-5 | PROTAC CDK9 degrader-5 is a PROTAC targeting to CDK9 sepcifically. |
| M43458 | SJ1008030 formic | SJ1008030 formic is a JAK2 PROTAC which selectively degrades JAK2. |
| M43457 | PF15 TFA | PF15 TFA is a PROTAC connected by ligands for FLT3 kinase and CRBN. |
| M43456 | ERK-CLIPTAC | ERK-CLIPTAC is a PROTAC molecule that triggers the degradation of ERK. |
| M43455 | Homo-BacPROTAC7 | Homo-BacPROTAC7 is a ClpC1NTD BacPROTAC degrader and can targets ClpC2. |
| M43454 | Homo-BacPROTAC6 | Homo-BacPROTAC6 is a ClpC1NTD BacPROTAC degrader and can targets ClpC2. |
| M43453 | PTD10 | PTD10 is a highly potent PROTAC BTK degrader (DC50: 0.5 nM, KD: 2.28 nM). |
| M43452 | SA-VA | SA-VA is an intracellular self-assembled PROTAC based on azide and alkyne. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
